NL301043I2 - Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat - Google Patents

Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat Download PDF

Info

Publication number: NL301043I2
Authority: NL; Netherlands
Prior art keywords: osilodrostat; optionally; pharmaceutically acceptable; acceptable salt; dihydrogen phosphate
Prior art date: 2010-01-14

Application number

NL301043C

Other languages

English (en)

Other versions

NL301043I1 (nl

Original Assignee

Recordati Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-14

Filing date

2020-06-10

Publication date

2020-07-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301043(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-06-10 Application filed by Recordati Ag filed Critical Recordati Ag

2020-06-17 Publication of NL301043I1 publication Critical patent/NL301043I1/nl

2020-07-06 Publication of NL301043I2 publication Critical patent/NL301043I2/nl

Links

USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 title 2
229950009981 osilodrostat Drugs 0.000 title 2
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL301043C 2010-01-14 2020-06-10 Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat NL301043I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29498010P	2010-01-14	2010-01-14
PCT/US2011/021100 WO2011088188A1 (en)	2010-01-14	2011-01-13	Use of an adrenal hormone-modifying agent

Publications (2)

Publication Number	Publication Date
NL301043I1 NL301043I1 (nl)	2020-06-17
NL301043I2 true NL301043I2 (nl)	2020-07-06

Family

ID=43735742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301043C NL301043I2 (nl)	2010-01-14	2020-06-10	Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat

Country Status (33)

Country	Link
US (2)	US8609862B2 (nl)
EP (2)	EP2523731B1 (nl)
JP (4)	JP5602250B2 (nl)
KR (1)	KR101412206B1 (nl)
CN (2)	CN105440038A (nl)
AU (1)	AU2011205290C1 (nl)
BR (1)	BR112012017458B1 (nl)
CA (1)	CA2786443C (nl)
CL (1)	CL2012001961A1 (nl)
CY (2)	CY1121320T1 (nl)
DK (1)	DK2523731T3 (nl)
ES (1)	ES2707596T3 (nl)
HR (1)	HRP20190064T1 (nl)
HU (2)	HUE041967T2 (nl)
IL (1)	IL220804A0 (nl)
LT (2)	LT2523731T (nl)
LU (1)	LUC00159I2 (nl)
MA (1)	MA33904B1 (nl)
ME (1)	ME03371B (nl)
MX (2)	MX2012008212A (nl)
NL (1)	NL301043I2 (nl)
NO (1)	NO2020012I1 (nl)
NZ (1)	NZ601077A (nl)
PL (1)	PL2523731T3 (nl)
PT (1)	PT2523731T (nl)
RS (1)	RS58234B1 (nl)
RU (1)	RU2598708C2 (nl)
SG (1)	SG182393A1 (nl)
SI (1)	SI2523731T1 (nl)
TN (1)	TN2012000352A1 (nl)
TR (1)	TR201900515T4 (nl)
WO (1)	WO2011088188A1 (nl)
ZA (1)	ZA201205058B (nl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2012008212A (es) *	2010-01-14	2012-08-03	Novartis Ag	Uso de un agente modificador de hormonas suprarrenales.
RU2674259C2 (ru)	2010-06-16	2018-12-06	Эмбера Ньюротерапьютикс, Инк	Композиции и способы лечения зависимости, психических расстройств и нейродегенеративного заболевания
AR086665A1 (es)	2011-06-14	2014-01-15	Lilly Co Eli	Inhibidor de aldosterona sintasa y composiciones farmaceuticas
WO2013043521A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Pyrazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043518A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en)	2011-09-22	2021-01-13	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
SI2804863T1 (sl) *	2012-01-17	2016-05-31	Novartis Ag	Nove oblike in soli zaviralca sinteze ali aromataze dihidropropirolo(1,2-c)imidazolil aldosterona
CA2869442C (en) *	2012-04-12	2020-09-08	Novartis Ag	Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
CA2886117C (en)	2012-10-05	2022-05-31	Merck Sharp & Dohme Corp.	Indoline compounds and their use as aldosterone synthase inhibitors
JP2015093832A (ja) *	2013-11-08	2015-05-18	日本メジフィジックス株式会社	放射性ハロゲン標識化合物又はその塩、これを含む医薬
JP6731136B2 (ja) *	2014-07-07	2020-07-29	レコルダティアーゲー	医薬製剤
WO2016048984A1 (en) *	2014-09-25	2016-03-31	Cortendo Ab (Publ)	Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
CA2973539A1 (en)	2015-01-29	2016-08-04	Novartis Ag	Process for the production of condensed imidazolo derivatives
WO2016164476A2 (en)	2015-04-06	2016-10-13	Millendo Therapeutics, Inc.	Combination therapy for treating disorders associated with excess cortisol production
CA2990413A1 (en) *	2015-06-22	2016-12-29	Embera Neurotherapeutics, Inc.	Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
BR112019018700A2 (pt)	2017-03-10	2020-04-07	Embera Neurotherapeutics Inc	composições farmacêuticas e seus usos

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4889861A (en) *	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en)	1987-07-28	1989-03-21	The Trustees Of Dartmouth College	Method for treatment of hypercortisolemic, depressed patients
US5503843A (en)	1994-04-22	1996-04-02	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en)	1994-10-14	1997-08-19	Twk, Inc.	Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de)	1998-03-30	1999-10-14	Lohmann Therapie Syst Lts	Feuchtigkeitsaktivierbares therapeutisches System
EP1121111B1 (en)	1998-10-15	2010-02-10	Imperial Innovations Limited	Compounds for the treatment of weight loss
IL157363A0 (en) *	2001-02-16	2004-02-19	Aventis Pharma Inc	Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
TWI263640B (en) *	2001-12-19	2006-10-11	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
JP5138875B2 (ja)	2005-07-19	2013-02-06	株式会社デンソー	センサ装置
GT200600381A (es) *	2005-08-25	2007-03-28		Compuestos organicos
TW200804378A (en)	2005-12-09	2008-01-16	Speedel Experimenta Ag	Organic compounds
US20090304661A1 (en)	2006-03-16	2009-12-10	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Sceince	Method And Composition For Proctecting Neuronal Tissue From Damage Induced By Elevated Glutamate Levels
MX2008015008A (es)	2006-05-26	2008-12-05	Novartis Ag	INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
EP1886695A1 (en)	2006-06-27	2008-02-13	Speedel Experimenta AG	Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
JP2010501573A (ja) *	2006-08-25	2010-01-21	ノバルティスアクチエンゲゼルシャフト	アルドステロン合成酵素および／または１１−β−ヒドロキシラーゼおよび／またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
WO2008076860A1 (en) *	2006-12-18	2008-06-26	Novartis Ag	4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
EP2095819A1 (en)	2008-02-28	2009-09-02	Maastricht University	N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
MX2012008212A (es) *	2010-01-14	2012-08-03	Novartis Ag	Uso de un agente modificador de hormonas suprarrenales.
SI2804863T1 (sl) *	2012-01-17	2016-05-31	Novartis Ag	Nove oblike in soli zaviralca sinteze ali aromataze dihidropropirolo(1,2-c)imidazolil aldosterona
CA2869442C (en) *	2012-04-12	2020-09-08	Novartis Ag	Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

2011
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Application Filing
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 RU RU2012134510/15A patent/RU2598708C2/ru active
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en active Application Filing
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
2019
- 2019-01-09 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I1/el unknown

Also Published As

Publication number	Publication date
EP2523731A1 (en)	2012-11-21
LT2523731T (lt)	2019-02-11
AU2011205290C1 (en)	2014-11-06
BR112012017458B1 (pt)	2020-10-20
CY2020018I2 (el)	2020-11-25
RU2012134510A (ru)	2014-02-20
TR201900515T4 (tr)	2019-02-21
ES2707596T3 (es)	2019-04-04
RU2598708C2 (ru)	2016-09-27
SG182393A1 (en)	2012-08-30
LUC00159I1 (nl)	2020-06-16
LUC00159I2 (nl)	2021-07-06
AU2011205290B2 (en)	2014-06-26
NZ601077A (en)	2014-07-25
LTPA2020512I1 (lt)	2020-07-27
CY2020018I1 (el)	2020-11-25
HUE041967T2 (hu)	2019-06-28
NO2020012I1 (no)	2020-06-09
CA2786443C (en)	2018-12-11
AU2011205290A1 (en)	2012-08-02
MA33904B1 (fr)	2013-01-02
TN2012000352A1 (en)	2014-01-30
DK2523731T3 (en)	2019-02-04
CN102711916B (zh)	2015-09-02
NL301043I1 (nl)	2020-06-17
US20120295888A1 (en)	2012-11-22
EP3527208A1 (en)	2019-08-21
CL2012001961A1 (es)	2013-03-22
PL2523731T3 (pl)	2019-04-30
JP2013517280A (ja)	2013-05-16
EP2523731B1 (en)	2018-10-24
LTC2523731I2 (lt)	2022-05-10
KR20120116482A (ko)	2012-10-22
RS58234B1 (sr)	2019-03-29
CN105440038A (zh)	2016-03-30
JP5602250B2 (ja)	2014-10-08
US8609862B2 (en)	2013-12-17
HUS2000018I1 (hu)	2020-07-28
JP6181610B2 (ja)	2017-08-16
CY1121320T1 (el)	2020-05-29
CA2786443A1 (en)	2011-07-21
BR112012017458A2 (pt)	2017-12-19
JP2015013859A (ja)	2015-01-22
KR101412206B1 (ko)	2014-06-25
JP2017002063A (ja)	2017-01-05
CN102711916A (zh)	2012-10-03
IL220804A0 (en)	2012-08-30
JP6425688B2 (ja)	2018-11-21
MX2012008212A (es)	2012-08-03
HUS000508I2 (hu)	2021-03-29
ME03371B (me)	2020-01-20
JP2018150326A (ja)	2018-09-27
MX354022B (es)	2018-02-08
SI2523731T1 (sl)	2019-02-28
PT2523731T (pt)	2019-01-21
ZA201205058B (en)	2014-04-30
US9434754B2 (en)	2016-09-06
US20140171392A1 (en)	2014-06-19
WO2011088188A1 (en)	2011-07-21
HRP20190064T1 (hr)	2019-03-08

Publication	Publication Date	Title
NL301043I2 (nl)	2020-07-06	Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat
NL301238I2 (nl)	2023-10-04	Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301041I2 (nl)	2020-09-14	Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan
NL300980I2 (nl)	2021-06-17	Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl)	2022-04-06	zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301155I2 (nl)	2022-02-23	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301191I2 (nl)	2022-12-07	voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301021I1 (nl)	2019-12-18	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300971I2 (nl)	2019-04-11	Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL301234I2 (nl)	2023-07-26	maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl)	2020-04-15	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan